

Amyloidosis: the use of the Daratumumab

Adriano Anzai¹
Armelin Utino¹
Haroldo Katayama¹
Ighor A. Z. Spir¹
Marcio A. Lemos¹
Mauricio Anhesini¹
Oswaldo S. Tiezzi¹
Patricia R. N. Spir¹
Pericles Otani¹
Wanderley M. Bernardo²

1. Grupo de M.B. E – Presidente Prudente, Presidente Prudente, SP, Brasil.
2. Coordenador do Programa Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brasil.

<http://dx.doi.org/10.1590/1806-9282.66.12.1620>

QUESTION: What is the role of daratumumab in the treatment of Amyloidosis?

ANSWER: The use of daratumumab in patients with clinical symptoms of amyloidosis currently should not

be recommended due to the weakness of the evidence available to support it.¹

REFERENCES

1. Anzai, Adriano et. al. Use of daratumumab in patients with amyloidosis. Rev Assoc Med Bras 2020; 66(11):1468-1471.

